2024
Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy
Moura F, Bellavia A, Berg D, Melloni G, Feinberg M, Leiter L, Bohula E, Morrow D, Scirica B, Wiviott S, Sabatine M. Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy. Diabetes Obesity And Metabolism 2024, 26: 4441-4449. PMID: 39056220, PMCID: PMC11410501, DOI: 10.1111/dom.15798.Peer-Reviewed Original ResearchNew-onset diabetesRisk of new-onset diabetesClinical risk modelWeight loss therapyRisk groupsWeight loss pharmacotherapyMultivariate Cox regressionStable cardiovascular patientsTherapeutic decision makingAbsolute risk reductionHigh-risk groupType 2 diabetesIndependent predictorsValidation cohortFollow-upPersonalized patient careCox regressionHazard ratioPrimary outcomeRisk modelHigh riskInterquartile rangePatientsDiabetesCardiovascular patients
2023
Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes
Moura F, Berg D, Bellavia A, Dwyer J, Mosenzon O, Scirica B, Wiviott S, Bhatt D, Raz I, Feinberg M, Braunwald E, Morrow D, Sabatine M. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care 2023, 46: 1807-1815. PMID: 37556796, PMCID: PMC10516252, DOI: 10.2337/dc23-0492.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Kidney disease progressionPredictors of kidney disease progressionAbsolute risk reductionDisease progressionValidation cohortType 2 diabetesSodium-glucose cotransporter 2 inhibitionUrine albumin-to-creatinine ratioAlbumin-to-creatinine ratioEfficacy of dapagliflozinMedian follow-upRisk categoriesMultivariate Cox regressionRelative risk reductionHigh-risk groupAtherosclerotic cardiovascular diseaseSystolic blood pressureRisk reductionMagnitude of benefitDapagliflozin EffectT2D durationCotransporter 2SGLT2 inhibitionStratify riskAssessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Berg D, Moura F, Bellavia A, Scirica B, Wiviott S, Bhatt D, Raz I, Bohula E, Giugliano R, Park J, Feinberg M, Braunwald E, Morrow D, Sabatine M. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. Journal Of The American College Of Cardiology 2023, 81: 2391-2402. PMID: 37344040, PMCID: PMC11466046, DOI: 10.1016/j.jacc.2023.04.031.Peer-Reviewed Original ResearchConceptsType 2 diabetes mellitusSecondary preventionIschemic strokePredictor of MIValidation cohortClinical decision-makingRates of MIMyocardial infarctionAtherothrombotic eventsRisk quintileRisk of atherothrombotic eventsRisk modelSelection of pharmacotherapyRisk scoreAssessed clinical variablesMultivariate Cox regressionClinical trial cohortPooled cohortCandidate variablesCox regressionIS ratesDECLARE-TIMIAbsolute reductionTrial cohortCohort